

A Pragmatic Approach to the Perioperative Management of Parkinson's Disease

Abhishek Lenka, Shivam Om Mittal, Guillaume Lamotte, Fernando Luis Pagan

ABSTRACT: Patients with Parkinson's disease (PD) may undergo several elective and emergency surgeries. Motor fluctuations, the presence of a wide range of non-motor symptoms (NMS), and the use of several medications, often not limited to dopaminergic agents, make the perioperative management of PD challenging. However, the literature on perioperative management of PD is sparse. In this descriptive review article, we comprehensively discuss the issues in the pre-, intra-, and postoperative phases which may negatively affect the PD patients and discuss the approach to their prevention and management. The major preoperative challenges include accurate medication reconciliation and administration of the dopaminergic medications during the *nil per os* (NPO) state. While the former can be addressed with staff education and PD-specific admission protocols, knowledge of non-oral formulations of dopaminergic agents (apomorphine, inhalational levodopa, and rotigotine transdermal patch) is the key to the management of the Parkinsonian symptoms in NPO state. Deep brain stimulation (DBS) devices should be turned off to avert potential electromagnetic interference with surgical appliances. Choosing the appropriate anesthesia and avoiding and managing respiratory issues and dysautonomia are the major intraoperative challenges. Timely reinitiation of dopaminergic medications, adequate management of pain, nausea, and vomiting, and prevention of postoperative infections and delirium are the postoperative challenges. Overall, a multidisciplinary approach is pivotal to prevent and manage the perioperative complications in PD. Administration of anti-Parkinson medications during NPO state, prevention of anesthesia-related complications, and timely rehabilitation remain the key to healthy surgical outcomes.

RÉSUMÉ : Une approche pragmatique de la prise en charge péri-opératoire des patients atteints de la maladie de Parkinson. Les patients aux prises avec la maladie de Parkinson (MP) peuvent être amenés à subir de nombreuses chirurgies électives et d'urgence. Des fluctuations de la motricité, la présence d'un large éventail de symptômes non moteurs et l'utilisation de plusieurs médicaments, souvent non limités aux agents dopaminergiques, sont autant d'aspects qui rendent davantage compliquée la prise en charge péri-opératoire de ces patients. Il faut convenir toutefois que la littérature portant sur cette prise en charge est rare. Dans cet article de synthèse descriptif, nous voulons à la fois aborder de manière exhaustive les enjeux propres aux phases préopératoire, intra-opératoire et post-opératoire qui pourraient affecter de manière négative les patients atteints de la MP et discuter de l'approche à adopter en matière de prévention et de prise en charge. Les principaux enjeux préopératoires incluent notamment une conciliation médicamenteuse exacte et l'administration de médicaments dopaminergiques au moment où les patients ne peuvent rien recevoir par voie orale (*nil per os* ou NPO). Bien qu'il soit possible de tenir compte du premier enjeu en formant les équipes de travail et en respectant des protocoles spécifiques d'admission des patients, le fait de bien connaître les formulations non-orales des agents dopaminergiques (l'apomorphine, la lévodopa par inhalation, les timbres transdermiques de rotigotine) demeure la clef de la prise en charge des symptômes parkinsoniens lorsque les patients sont dans un état dit « NPO ». Les appareils de stimulation cérébrale profonde (SCP) devraient avoir été éteints pour éviter d'éventuelles interférences électromagnétiques avec les appareils chirurgicaux. Choisir l'anesthésie appropriée, mais aussi éviter ou bien gérer des problèmes respiratoires et la dysautonomie, sont les enjeux intra-opératoires les plus importants. D'un autre côté, recommencer en temps opportun à administrer des médicaments dopaminergiques, prendre en charge de manière adéquate la douleur, les nausées et les vomissements et prévenir des infections postopératoires ainsi que des manifestations de délire sont les principaux enjeux post-opératoires. De façon générale, une approche multidisciplinaire est essentielle afin de prévenir les complications péri-opératoires chez des patients atteints de la MP et d'assurer leur prise en charge. L'administration de médicaments antiparkinsoniens en cours de « NPO », la prévention des complications liées à l'anesthésie et une réadaptation en temps utile demeurent en somme la clef d'une amélioration de leur état de santé.

Keywords: Parkinson's disease, Surgery, Anesthesia, Perioperative

doi:10.1017/cjn.2020.211

Can J Neurol Sci. 2021; 48: 299–307

INTRODUCTION

Parkinson's disease (PD) is a chronic, progressive neurodegenerative disease. The cardinal motor symptoms of PD are tremor at rest, rigidity, bradykinesia, and postural instability. An array of non-motor symptoms (NMS) complicates the clinical course of most of the patients.¹ The estimated prevalence of PD in developed countries is 0.3% of the general population; however, the prevalence increases with age (>1% in people >60 years, >3% in people >80 years).² The elderly population is not only burdened with a higher PD prevalence but also with several

age-related comorbidities necessitating surgeries.³ The surgeries may be elective or emergent and may be directly (deep brain stimulation (DBS)) or indirectly (for treatment of injuries related to recurrent falls) related to PD or may be unrelated as well

From the Department of Neurology, Georgetown University Hospital, Washington, DC, USA (AL, FLP); Department of Neurology, Cleveland Clinic, Abu Dhabi, United Arab Emirates (SOM); and Department of Neurology, Mayo Clinic, Rochester, MN, USA (GL)

RECEIVED JULY 16, 2020. DATE OF ACCEPTANCE SEPTEMBER 16, 2020.

Correspondence to: Dr. Abhishek Lenka MD, Ph.D., Department of Neurology, Georgetown University Hospital, Washington, DC, 20007, USA, Email: gemsabhishek@gmail.com

(cataract surgeries, gastrointestinal surgeries, joint replacement surgeries, onco-surgeries, etc.). With the expansion of knowledge on NMS, PD is no longer considered a simple motor disorder of basal ganglia pathology, rather it is now being recognized as a clinically heterogeneous multisystem disorder.⁴ The existence of a large constellation of motor and NMS (Table 1) in elderly patients who are on several medications, often not limited dopaminergic agents, makes the management of the perioperative phase challenging. A population-based study in Taiwan revealed that patients with PD undergoing non-neurological surgeries have higher 30-day mortality and have a greater risk of having postoperative major complications including pulmonary embolism, stroke, pneumonia, septicemia, acute renal failure, and urinary tract infection (UTI).⁵ Considering the challenges involved in the management of PD patients in the perioperative phase, it is crucial for the neurologists, anesthesiologists, and surgeons to be aware of the risks and complications to prevent and manage them effectively.

The literature on perioperative management of PD is sparse. Moreover, substantial advances in PD therapeutics warrant updates in the knowledge about perioperative management of PD. This article revisits the important perioperative issues in PD and comprehensively describes the pragmatic approach to their management, taking into account the recent advances in the field of PD.

PREOPERATIVE CONSIDERATIONS

Accurate Reconciliation and Timely Administration of Home Medications

Patients with PD are advised to have their anti-Parkinson medications at specific times of the day or fixed intervals daily. Deviations in the schedule of such medications may result in bothersome adverse effects such as motor fluctuation and that, in turn, can be associated with fluctuations in the NMS of PD.^{6,7} However, erroneous reconciliation (dose/route/frequency) of these time-sensitive medications is not uncommon for hospitalized PD patients. A large retrospective study from Spain (1628 patients, 2546 admissions) revealed that medication errors during hospitalization (in one-third of the admissions and half of the patients) were associated with higher mortality in PD.⁸ Several other studies have documented medication error rates ranging from 23% to 76% in hospitalized PD patients.^{9–11} The commonly documented errors include omission and/or incorrect scheduling of the dopaminergic agents, and administration of medications with relative contraindications in PD (e.g. older antipsychotics, antiemetics with dopamine-blocking property, and anticholinergics).

The reconciliation errors are probably higher for emergency hospitalizations, especially when the patients are on several medications that are non-formulary in the inpatient pharmacy. If patients have the non-formulary medications with them during the admission, the inpatient pharmacy verifies and lists the medications as “patient’s own medication”. Hence, patients may miss a dose or get an incorrect dose if the pharmacy delays the verification or does an inaccurate documentation of the medications and their doses. However, as mentioned above, patients are unlikely to carry their home medications during emergency hospitalization, which leads to incomplete medication reconciliation. The seemingly minor deviations in the anti-Parkinson treatment regimen may culminate in major issues directly (severe OFF-state, worsening of dyskinesias, dysphagia) or indirectly

associated with PD (aspiration pneumonia, delirium, and falls).^{9,10} Hence, strict adherence to PD patients’ individualized medication regimen is crucial. Education of the staff and effective implementation of PD-specific admission protocols may avoid complications during the perioperative phase and improve the outcomes of hospitalized PD patients.^{11–13} The Parkinson’s Foundation recommends using the “Aware in Care” kit, which helps in planning a safe hospitalization.¹⁴

Addressing the NMS During the Hospital Stay

A plethora of NMS complicates the clinical course of PD by potentially affecting all the physiological systems. Certain NMS such as sleep disturbances, psychosis, pain, sialorrhea, constipation, and those resulting from dysautonomia (orthostatic symptoms, bladder disturbances) can be bothersome during the perioperative state. It is important in the preoperative state to document the NMS using the appropriate screening instruments.¹⁵ Comprehensive documentation of the NMS before the procedures not only helps in distinguishing the NMS related to PD from those secondary to the procedures (delirium, urinary retention, pain, etc.) but also for effective management of such symptoms. Table 1 succinctly summarizes the NMS in PD and their perioperative implications. Comprehensive management of the NMS in PD is beyond the scope of this review and it is described in detail elsewhere.¹⁶

Managing Parkinsonian Symptoms During NPO Status

One of the common prerequisites of all the surgeries under anesthesia is “nothing through mouth” (Latin – *nil per os* or NPO) status; however, oral medications may be taken by mouth with a sip of water almost up to the time of surgery in most cases and a strict NPO order is usually reserved for special circumstances (e.g. major gastrointestinal surgeries). However, several factors including the NPO status, knowledge gap of healthcare providers, and delays related to the hospital delivery system may result in prolonged periods of medication withholding. A retrospective analysis of 89 separate surgical events for 67 discrete PD patients revealed a median withholding duration of 12.35 h for carbidopa-levodopa (C/L).¹⁷ The median withholding duration was longer for inpatient procedures (16.75 h) than for the outpatient procedures (11.38 h). In the same study, 62% of the surgeries resulted in medication withholding duration between 10 and 20 h and 17% of the surgeries resulted in withholding times of >20 h.¹⁷

The physician should consider allowing the administration of PD medications as close as possible to the patient’s medication schedule preoperatively. Scheduled surgery should ideally happen early in the day to promote the best symptom management and limit the risk of complications and discomfort related to missed doses. Keeping the PD patients under strict NPO status is challenging because almost all the major anti-Parkinsonian medications are available only with oral formulations. Involving a Movement Disorders Neurologists or Neurologists with knowledge in PD management is recommended to help with change in medication regimen. As dopamine withdrawal syndrome can be devastating,¹⁸ it is essential to be aware of alternative therapeutic options. Among the currently available anti-Parkinsonian medications, orally disintegrating C/L and non-oral formulations of levodopa or dopamine agonists such as rotigotine and apomorphine (sublingual/subcutaneous injections/pump) can be

Table 1. Summary of commonly observed non-motor symptoms in Parkinson's disease, perioperative risk factors, and prevention

Non-motor Domains	Common non-motor symptoms	Perioperative risk factors	Prevention
Cardiovascular	Orthostatic intolerance, syncope	Change in fluid status, low salt intake, effect of anesthetics and new medications (i.e. sleep aids).	Careful management of fluid status, high salt diet if needed, limit drugs that cause orthostatic hypotension, leg stockings.
Sleep/fatigue	Excessive daytime sleepiness, insomnia, restless legs, and fatigue, RBD	Frequent nursing assessments, pain associated with surgery, change in sleep pattern, medications with sedative effect (i.e. antipsychotic).	Identify the cause of sleep disturbance, limit sleep interruption, avoid sedative drugs during the day. Cognitive-behavioral therapy for insomnia, pharmacological treatment (dopamine agonists, melatonin, eszopiclone).
Perceptual problems	Hallucinations, delusions, and double vision	Postoperative delirium or exacerbation of preexisting psychosis due to infection, fluid-electrolyte imbalance, adverse drug reactions (i.e. anticholinergic).	Careful assessment of treatment regimen and drug-drug interaction, identify and treat infection and fluid-electrolyte imbalance promptly.
Gastrointestinal	Dysphagia, constipation	Immobility, change in diet, adverse drug reactions (i.e. opioids), sub-optimal oral care, oral secretion.	Early mobility with physical therapy, raise the head of the bed, adapt diet consistency, use bowel regimen, good oral hygiene.
Secretion	Sialorrhea, increased respiratory secretions	Immobility and supine position.	Importance of early mobility and incentive spirometry to prevent aspiration.
Urinary	Urgency, frequency, retention, nocturia	Urinary tract infections, adverse drug reactions (i.e. anticholinergic).	Early mobility with physical therapy, maintain good hydration, careful assessment of drug side effects, early identification and treatment of infection.
Mood/cognition	Poor attention, memory impairment, apathy, anxiety, and depression	Maybe worsened in the perioperative state, social isolation, and hypoactive delirium.	Maintain circadian rhythm, frequent reorientation, early mobility, minimize deliriogenic drugs, consider antidepressant drugs if comorbid depression.
Miscellaneous	Pain	Immobility, change in treatment for Parkinson's disease (off symptom).	Pain associated with Parkinson's disease should be differentiated from the pain related to surgery and treated appropriately.

considered. Table 2 summarizes the dose conversions, advantages, and disadvantages of these non-oral alternatives of levodopa.

INTRAOPERATIVE CONSIDERATIONS

Challenges in Positioning and Monitoring

Problems with proper positioning may arise in patients with inadequately managed Parkinsonian symptoms in the setting of regional anesthesia. While general anesthesia would temporarily suppress the Parkinsonian symptoms, those under regional anesthesia may have persistence of rigidity in the neck or in the extremities and tremor of several parts of the body. Such scenarios reinforce the importance of optimal dopamine replacement therapy in the preoperative phase as described above. Infrequently, patients may have other PD-associated musculoskeletal deformities such as camptocormia, striatal hand, and foot deformities which would potentially make proper positioning of patients challenging.¹⁹ Hence, depending on the site of surgery, proper planning regarding the type of anesthesia and positioning should be done in advance.

Monitoring of several physiological parameters such as temperature, blood pressure, and cardiac rhythm may be affected by a number of PD-associated factors. For example, thermoregulatory dysfunction is common in PD, resulting in heat and cold intolerance. Although rare, the anesthesiologists should be mindful of the possibilities of spontaneous periodic hypothermia in PD

patients which can have certain EKG and EEG correlates.^{20–22} Similarly, hyperthermia can be a manifestation of the Parkinsonism-hyperpyrexia syndrome which usually results from the abrupt cessation of the dopaminergic agents.²³ Hence, abrupt changes in temperature should be closely monitored in the intraoperative phase. In patients undergoing regional anesthesia, the presence of tremors can result in artifacts in the EKG which mimic atrial flutter or ventricular fibrillation. In addition, excessive sweating due to dysautonomia may result in poor EKG electrode contact with the skin. Hence, an abrupt change in cardiac rhythm should prompt a look into these common artifacts.

Addressing the Common Respiratory and Cardiovascular Complications

Several studies have reported suboptimal respiratory function in PD patients.^{24–26} Both restrictive and obstructive patterns of involvement have been reported, with the improvement of the former with *C/L*.²⁵ Older age and general anesthesia during surgical emergencies may further worsen the suboptimal respiratory function in PD patients. One of the major intra- and postoperative issues in PD is the risk of aspiration pneumonia. The incidence of postoperative aspiration pneumonia is higher in PD compared to patients without PD,²⁷ which could be attributed to the impaired cough reflex,²⁸ defective motor control for cough,²⁹ and dysphagia in the elderly PD population.³⁰ Although there are no specific guidelines for managing acute respiratory issues, knowledge of the risk of

Table 2. Alternatives to oral levodopa/carbidopa in the perioperative setting in Parkinson's disease

Alternatives (Route)	Dose calculation	Advantages	Disadvantages
Disintegrating (C/L) (sublingual)	Conversion – 1:1	Availability	AE: Nausea
	Available dose: C/L (25/100), C/L (25/250)	Easy to administer	Not widely available
Inhaled Levodopa (oral inhalation)	Conversion – 1:1	Bypasses GI system	AE: Cough, nausea
	Available dose: 42 mg capsule	Bioequivalent	Needs active participation (cannot be given to intubated patients)
	Recommended dose: two capsules (84 mg) as a single dose, not more than five doses per day.	Not widely available	
CLES/LCIJ (intestinal gel) (infusion through pump)	20 mg/ml (max. recommended dose- 2000 mg/d)	Continuous delivery	Requires surgical procedure
	Morning dose (ml): LED × 0.8/20 over 10–30 min	Can be used during prolonged NPO (even during surgery)	
	Continuous dose: Remaining LED over 16 h		
Rotigotine (Transdermal patch)	Divide the LED by 30	Easy availability	AE: skin irritation hallucinations, and confusion
	Available dose: 2 mg, 4mg, 6 mg, and 8 mg	Easy to administer	
		Can be used during prolonged NPO (even during surgery)	
Apomorphine (SC inj, pump, Sublingual)	Divide the LED by 10	Easy to administer	AE: Nausea, vomiting, skin irritation, and OH.
	Inj. dose: start with 2mg, can be increased to 10 mg gradually	Can be continuously delivered (pump)	Not widely available
	Sublingual dose: 10–30 mg films,	Need for prior apomorphine test	
	Maximum of five doses/day with a maximum single dose of 30 mg, minimum inter-dose interval: 2 h		

AE = Adverse effects; C/L = carbidopa/levodopa; CLES = carbidopa-levodopa enteral suspension; GI = gastrointestinal; LED = Levodopa equivalent dose; NPO = *Nil per os*; OH = orthostatic hypotension; SC = subcutaneous.

respiratory complications in PD would keep the surgery and anesthesiology teams better prepared. Airway management may be challenging in PD patients, especially those with sialorrhea and dystonic neck posturing. Although uncommon, there are reports of postoperative laryngospasm and respiratory failure in PD.^{31,32} Hence, there should be a low threshold to go for chest X-rays, arterial blood gas analysis, and chest physical therapy if PD patients show signs of respiratory abnormalities.

The anesthesiology and surgical teams should be familiar with the potential cardiovascular comorbidities associated with PD. Dysautonomia is common in elderly PD patients, more so in those with advanced PD. The wide fluctuation of blood pressure during anesthesia should be quickly recognized and persistent hypotension in PD can be managed with the α 1-adrenoreceptor agonist phenylephrine.³³ Supine hypertension during surgery can be managed with short-acting intravenous vasodilators or with transdermal nitrates in the perioperative setting.³⁴ Finally, careful evaluation and control of blood volume are key in patients with PD and autonomic failure. Knowledge about patients' history of dysautonomia is important as trivial pharmacological alterations or surgery-related pain may trigger profound fluctuations in the cardiovascular parameters of PD patients.³⁵ Some common medications taken by PD patients have the potential to prolong the QT interval, which in the context of

general anesthesia can make the patients more vulnerable to arrhythmias. For example, antiemetics such as ondansetron, antipsychotics such as pimavanserin and quetiapine, and antidepressants such as citalopram are associated with QT-prolongations. Hence, the treating teams should be vigilant about the dose of these medications, more so in elderly patients with dysautonomia and other cardiac comorbidities.

Intraoperative Anesthetic Considerations

There is no simple anesthetic regimen for patients with PD and the evidence about the safety of anesthetic drugs is based on case reports or case series. When suitable, regional or central neuraxial block offers several benefits. These include patient cooperation while assessing Parkinsonian symptoms, availability of oral dopaminergic agents during intraoperative phase, no requirement for neuromuscular blocking agents and anticholinergic reversal agents, reduced or no use of systemic opioids. On the contrary, the presence of severe rigidity and tremor in parts of the body not under anesthesia may make positioning and monitoring difficult. General anesthesia would eliminate this disadvantage by abolishing the Parkinsonian symptoms, but at the cost of some other disadvantages (postoperative nausea, vomiting, higher risk of aspiration pneumonia). Hence, in addition to the nature of the

Table 3. Summary of the medications that should be preferably avoided because of direct adverse effects or interactions with MAO inhibitor

Class of medication	Common medications	Reason to avoid	Alternative medications
Medications which should be preferably avoided in patients with PD			
Anti-emetics	Metoclopramide, Droperidol, Promethazine, Prochlorperazine	Worsens Parkinsonian symptoms due to dopamine-blocking property	Ondansetron, Domperidone, and Trimethobenzamide.
Anti-psychotics	Haloperidol, Fluphenazine, Flupentixol, Risperidone, Olanzapine, Ziprasidone	Worsens Parkinsonian symptoms due to dopamine-blocking property	Clozapine, Pimavanserin, and Quetiapine
Anesthetics	Halothane	Risk of cardiac arrhythmia	Propofol and most of the other volatile anesthetic agents are safe
Opioid analgesics	Fentanyl, Alfentanil	Increases muscular rigidity	Morphine, Oxycodone, Codeine, Buprenorphine
Medications which should be avoided in patients taking MAO inhibitors (selegiline, rasagiline, safinamide)			
Opioid analgesics	Meperidine, Tramadol, Methadone, Propoxyphene	High risk for serotonin syndrome	Morphine, Oxycodone, Codeine, Buprenorphine
Anti-depressants	SSRIs, SNRIs, Tranylcypromine, Bupropion	High risk for serotonin syndrome	non-SSRIs
Cough suppressant	Dextromethorphan	High risk for serotonin syndrome	Codeine
Antibiotics	Linezolid	High risk for serotonin syndrome	Others without serotonin or MAO inhibiting properties

MAO = monoamine oxidase inhibitor; PD = Parkinson's disease; SNRI = selective norepinephrine uptake inhibitors; SSRI = selective serotonin reuptake inhibitors.

surgical procedure, severity and laterality of the preoperative Parkinsonian symptoms should be taken into account while deciding about the type of anesthesia. Because of suboptimal respiratory function associated with PD, anesthesia recovery time and extubation time should be optimized. Table 3 summarizes the medications that should be avoided or should be used with caution because of significant adverse effects or interactions.

In the case of general anesthesia, a rapid sequence induction is preferred to achieve rapid control of the airway whilst minimizing the risk of regurgitation and aspiration of gastric contents. Propofol is a commonly used anesthetic agent, which is given intravenously both for induction and maintenance. However, there are reports of dyskinesia associated with the use of propofol in patients with and without PD. The emergence of choreic and dystonic dyskinesias was reported after the administration of propofol in two patients undergoing pallidotomy.³⁶ Both the patients developed dyskinesia after getting 30 mg bolus of propofol, which subsided within a few minutes after discontinuing propofol in one patient and after giving midazolam to one patient. Although it is unclear how propofol is associated with such involuntary movements, it is speculated that the subtle anti-Parkinson effect of propofol could be contributory.³⁶ Although rare, oculogyric crisis³⁷ and acute dystonia³⁸ were reported with the use of propofol. Despite these adverse effects, propofol remains the anesthetic of choice in patients with PD owing to its rapid onset of action and overall safety.³⁹ If it occurs, propofol-induced dyskinesia can subside with the administration of dexmedetomidine.⁴⁰ Thiopental should be avoided as it may worsen Parkinsonism and the use of ketamine can be associated with cardiovascular complications.⁴¹ The effects of inhalational anesthetic in PD are complex. Although isoflurane may influence dopamine transmission through inhibition of the presynaptic dopamine active transporter (DAT),⁴² it is thought to be generally safe in PD. Other inhalational anesthetic agents such as sevoflurane and enflurane can be used in patients with PD, however,

intraoperative evaluation and optimization of blood volume are key to prevent hypotension. Halothane should be avoided in PD because of its potential arrhythmogenic effect and the risk of increased cardiac sensitivity to catecholamines.⁴³

Opioids can be used as anesthesia adjuncts or primary anesthetic agents for procedures performed under general, regional, or local anesthesia. Opioids should be used with caution in PD because of the risk of respiratory depression, acute dystonic reaction, muscle rigidity, and prolonged postoperative confusion and hallucinations.^{43,44} Patients with PD may be particularly sensitive to opioid-induced muscle rigidity, which has been reported with fentanyl.^{44,45} Opioid-induced muscle rigidity responds to neuromuscular blockade and naloxone.^{46,47} The combination of meperidine and selegiline should be avoided as it can provoke agitation, muscle rigidity, and hyperthermia.⁴⁸ Non-depolarizing neuromuscular blocking agents are recommended (e.g. rocuronium) as they do not worsen the Parkinsonian symptoms.⁴¹ Careful assessment of hydro-electrolyte disorders is important to prevent hyperkalemia with depolarizing neuromuscular blocking agents.⁴⁹

Intraoperative Issues in Patients with Implantable Deep Brain Stimulator

Electromagnetic Interference with the DBS Device

PD patients with DBS devices need additional care during the surgery. This is because of the possibility of electromagnetic interference with the implantable pulse generator (IPG) by the electrical appliances used during surgery and resuscitations, which often include, but not limited to diathermy, electrocautery, external cardiac defibrillator, cardiac monitoring, and electrocardiogram. Electromagnetic interference can damage the IPG, resulting in decreased or increased stimulation or complete cessation of output. There are reports of

reversible neurological symptoms and irreversible brain injury which resulted because of the interaction of diathermy and DBS.^{50,51} Electrosurgical units usually use two different configurations, i.e. monopolar and bipolar. Given significant adverse effects associated with the monopolar configuration in the context of metallic implants, it is prudent to use only the bipolar electrosurgical device.⁵² In addition, use of the relatively newer options such as PLASMABLADE and HARMONIC scalpels have good track records of safety and may be considered when available.^{53–55}

To summarize, the IPG should be turned off during the surgery, diathermy should be avoided, and bipolar electrosurgical devices should be preferred over the monopolar devices. At the end of the procedure, the IPG should be turned on to the baseline settings. If surgery was performed under general anesthesia, the IPG should ideally be turned on before the reversal of anesthesia to avoid the recurrence of Parkinsonian symptoms when the patient is awake.

POSTOPERATIVE CONSIDERATIONS

ReInitiation of the Anti-Parkinsonian Medications

Unless contraindicated from the surgery standpoint, the oral anti-Parkinsonian medications should be resumed at the earliest. However, several postoperative issues prompt alterations to the treatment regimen. For example, in PD patients with postoperative delirium, it would be appropriate to withhold medications that may precipitate delirium. These include amantadine and dopamine receptor agonists such as pramipexole and ropinirole. In such scenarios, short-term augmentation in the dose of C/L may be considered up to a dose similar to the preoperative levodopa equivalent dose (LED). In certain gastrointestinal surgeries, neither oral feeding nor nasogastric (NG) or orogastric (OG) tube feeding is possible several hours after the surgery. Such situations warrant judicious use of non-oral alternatives (with rotigotine patch, apomorphine injections) suggested above in the preoperative section.

Several situations may warrant feeding only through NG/OG tube temporarily or through gastrostomy tubes (G-tubes) permanently in patients with advanced PD. Anti-Parkinsonian regimens may be modified in those cases as several formulations (capsules, extended-release preparations) are not recommended through the NG/OG/G-tubes. The nursing team should be instructed to discontinue tube-feeding at least 30 min before and after giving C/L as interaction with protein-rich food reduces its absorption. Similarly, co-administration with vitamin-B6 should be avoided as the vitamin B6 accelerates the systemic metabolism of levodopa.⁵⁶

Pain Control

Pain related to the recent surgery should be differentiated from the pain sometimes associated with Parkinsonism. Pharmacological therapies such as paracetamol and nonsteroidal anti-inflammatory drugs should be considered first-line for postsurgical pain if there is no contraindication. Opioids should be used with caution in PD, and opioids with SSRI properties should be avoided in those taking monoamine oxidase B (MAO-B) inhibitors (selegiline/rasagiline/safinamide). Such opioids include tramadol, methadone, dextromethorphan, and

propoxyphene. Co-administration with the MAO-B inhibitors may cause heightened serotonin activity (serotonin syndrome) which encompasses symptoms such as agitation, rigidity, diaphoresis, hyperpyrexia, and even death. Safer analgesics (without SSRI property) include morphine, codeine, oxycodone, and buprenorphine. Special care needs to be taken for PD patients, as these patients can have worsening of constipation with the opioid analgesics and increased risk of delirium, and pulmonary complications secondary to opioids induce respiratory depression.

Nausea and Vomiting

Nausea and vomiting are common in the postoperative phase. Regarding antiemetic agents, ondansetron, trimethobenzamide (FDA-approved for postoperative nausea), and domperidone (not available in the USA) are preferred in patients with PD. Trimethobenzamide was effective in ameliorating nausea and vomiting in patients on subcutaneous apomorphine (in the first 8 weeks) without any significant adverse effect.⁵⁷ Given their dopamine receptor blocking properties, medications such as metoclopramide, prochlorperazine, and promethazine should be avoided.⁵⁸

Postoperative Delirium and Psychosis

The prevalence of postoperative delirium in PD ranges from 11% to 60%. Such variability could be explained by differences in the criteria used for the diagnosis of delirium.⁵⁹ The spectrum of manifestation of delirium is wide and previous studies have reported confusion, disorientation, hallucinations, agitation, hypomania as symptoms of delirium.⁵⁹ Delirium has an association with length of hospitalization, motor severity of PD, and older age.^{59,60} A study that investigated the non-motor correlates of postoperative delirium in PD patients undergoing spinal surgeries reported hyposmia and rapid eye movement sleep behavior disorder (RBD) as independent risk factors for delirium.⁶¹ As delirium can substantially worsen the overall outcome of PD patients, it needs effective prevention strategies (described in the preoperative section) and prompt management. One of the foremost steps in treating delirium is removal of the offending factors, especially the medications that could precipitate delirium. These include certain anti-Parkinsonian medications such as amantadine, dopamine receptor agonists, MAO-B inhibitors, and anticholinergics. Use of opioid analgesics and fluoroquinolone antibiotics should also be carefully monitored. Use of clozapine, pimavanserin, and quetiapine may be considered for patients with florid psychotic symptoms.^{62,63}

Prevention of Postoperative Infections

Large retrospective studies have reported a significantly higher incidence of postoperative infections in PD patients, compared to those without PD.^{5,27} Aspiration pneumonia and UTIs are the commonly reported infections. Impaired swallowing and poor cough reflex in the setting of general anesthesia results in suboptimal airway protection, increasing the risk of aspiration pneumonia. Hence, strict precautions should be taken to prevent aspiration pneumonia, which is a common cause of death among PD patients.^{64,65} Early interventions through the speech and language pathologists, chest physical therapy, and incentive spirometry are




Figure 1. Summary of the potential perioperative challenges associated with the care of patients Parkinson's disease.

recommended postoperatively. Bladder dysfunction, often compounded with benign hyperplasia of the prostate in elderly PD patients, may be associated with UTIs in PD patients.⁶⁶ If such patients develop urinary retention or incontinence, the threshold for urology consultation should be low. Postoperative urinary retention (POUR) is common with a reported incidence of 5%–70% in the general population.⁶⁷ Although there is no data on the incidence of POUR in PD, the presence of clinical/subclinical dysautonomia would place the older PD patients at a higher risk of having POUR. POUR would require urethral catheterization which, in turn, increases the risk of UTIs.⁶⁸ Hence, prompt identification and management should be done with the help of the urologists. Any signs of infection in the postoperative phase should prompt urinalysis, and if needed, urine culture to rule out UTI.

Multidisciplinary Approach

Because of the wide variety of both motor symptoms and NMS and the risk for perioperative morbidity in PD patients, a multidisciplinary approach is a key to provide optimal management in the perioperative setting. Importantly, treatment plans should be tailored to the needs of each patient. Timely administration of the right anti-Parkinson medications with the right dose and frequency is not as simple as it sounds. Adequate coordination between the admitting team, nurses, and pharmacy would prevent the medication reconciliation and administration errors. An integrated care approach is viable and should be emphasized, through the contribution of the nursing staff and different specialties such as neurology, anesthesiology, internal medicine, and sometimes cardiology, urology, or gastroenterology. Finally,

early involvement of physiotherapy, occupational therapy, and speech-language therapy may help PD patients to avoid deconditioning while hospitalized and reduce the risk of postoperative complications such as aspiration pneumonia. Figure 1 summarizes the common perioperative issues in patients with PD.

CONCLUSION

Patients with PD are at a high risk of complications in the perioperative setting. A multidisciplinary approach is pivotal to prevent and manage those complications. Accurate medication reconciliation during admissions, continuation of appropriate dopaminergic agents up to the level of pre-hospitalization LED, and prompt use of the alternative routes of drug administration are the keys to an uneventful preoperative phase. Turning off the DBS-IPGs just before surgery, avoiding the diathermy and monopolar surgical appliances, opting for the appropriate anesthetic agents, and prompt identification and management of respiratory and cardiovascular complications are important in the intraoperative period. Eventually, the management in the postoperative phase should focus on adequate management of pain, nausea, and vomiting, prevention of delirium, aspiration pneumonia, and UTI, and early rehabilitation. These approaches are important for safe hospitalization and better clinical outcome of PD patients undergoing surgeries.

CONFLICTS OF INTEREST

The authors declare that there are no conflicts of interest relevant to this work.

STATEMENT OF AUTHORSHIP

- (1) **Research Project:** A. Conception, B. Organization, C. Execution.
- (2) **Manuscript:** A. Writing of the First Draft, B. Review and Critique.

AL: 1 A, 1B, 1C, 2A.
 SOM: 1 A, 1B, 1C, 2A.
 GL: 1B, 1C, 2B.
 FLP: 1C, 2B.

DISCLOSURES

Drs. Lenka, Mittal, and Lamotte have no disclosures to report.

Dr. Pagan reports receiving personal fees and other support from Acadia, AbbVie, Kwowa-Kirin, Accorda, and Adamas; personal fees from Teva; grants from Medtronic; grants, personal fees, and other from the US World Meds; grants from the National Institutes of Health, National Institute on Aging; grants from the Alzheimer's Association and National Institutes of Health as co-principal investigator, and Parkinson's Foundation, and personal fees and other from Sunovion and Merz outside the submitted work. Dr. Pagan is a co-founder and has equity in KiefRx.

REFERENCES

1. Kalia LV., Lang AE. Parkinson's disease. *Lancet*. 2015;386(9996):896–912. doi: [10.1016/S0140-6736\(14\)61393-3](https://doi.org/10.1016/S0140-6736(14)61393-3)
2. de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. *Lancet Neurol*. 2006;5(6):525–35. doi: [10.1016/S1474-4422\(06\)70471-9](https://doi.org/10.1016/S1474-4422(06)70471-9)
3. Etzioni DA, Liu JH, O'Connell JB, Maggard MA, Ko CY. Elderly patients in surgical workloads: A population-based analysis. *American Surgeon* 2003;69(11):961–65.
4. Klingelhöfer L, Reichmann H. Parkinson's disease as a multisystem disorder. *J Neural Transm*. 2017;124:709–13. doi: [10.1007/s00702-017-1692-0](https://doi.org/10.1007/s00702-017-1692-0)
5. Huang YF, Chou YC, Yeh CC, et al. Outcomes after non-neurological surgery in patients with Parkinson's disease a nationwide matched cohort study. *Med (United States)*. 2016;95(12):1–7. doi: [10.1097/MD.00000000000003196](https://doi.org/10.1097/MD.00000000000003196)
6. Kim A, Kim HJ, Shin CW, et al. Emergence of non-motor fluctuations with reference to motor fluctuations in Parkinson's disease. *Park Relat Disord*. 2018;54(79):83. doi: [10.1016/j.parkreldis.2018.04.020](https://doi.org/10.1016/j.parkreldis.2018.04.020)
7. Martínez-Fernández R, Schmitt E, Martínez-Martin P, Krack P. The hidden sister of motor fluctuations in Parkinson's disease: A review on nonmotor fluctuations. *Mov Disord*. 2016;31(8):1080–94. doi: [10.1002/mds.26731](https://doi.org/10.1002/mds.26731)
8. Lertxundi S, Isla A, Solinís MÁ, et al. Medication errors in Parkinson's disease inpatients in the Basque Country. *Parkinsonism Relat Disord*. 2017;36:57–62. doi: [10.1016/j.parkreldis.2016.12.028](https://doi.org/10.1016/j.parkreldis.2016.12.028)
9. Derry CP, Shah KJ, Caie L, Counsell CE. Medication management in people with Parkinson's disease during surgical admissions. *Postgrad Med J*. 2010;86(1016):334–7. doi: [10.1136/pgmj.2009.080432](https://doi.org/10.1136/pgmj.2009.080432)
10. Magdalino KN, Martin A, Kessel B. Prescribing medications in Parkinson's disease (PD) patients during acute admissions to a District General Hospital. *Park Relat Disord*. 2007;13(8):539–40. doi: [10.1016/j.parkreldis.2006.11.006](https://doi.org/10.1016/j.parkreldis.2006.11.006)
11. Lance S, Travers J, Bourke D. Reducing medication errors for hospital inpatients with Parkinsonism. *Intern Med J*. 2020. doi: [10.1111/imj.14782](https://doi.org/10.1111/imj.14782)
12. Aminoff MJ, Christine CW, Friedman JH, et al. Management of the hospitalized patient with Parkinson's disease: Current state of the field and need for guidelines. *Park Relat Disord*. 2011;139–45. doi: [10.1016/j.parkreldis.2010.11.009](https://doi.org/10.1016/j.parkreldis.2010.11.009)
13. Aslam S, Simpson E, Baugh M, Shill H. Interventions to minimize complications in hospitalized patients with Parkinson disease. *Neurol Clin Pract*. 2020;10(1):23–8. doi: [10.1212/cpj.0000000000000709](https://doi.org/10.1212/cpj.0000000000000709)
14. Parkinson's Foundation. Parkinson's Foundation. Available at: https://secure3.convio.net/prkorg/site/Ecommerce/40694200?VIEW_PRODUCT=true&product_id=1361&store_id=4003&_ga=2.107623298.1095769277.1590976209-175218503.8159831727. Published 2020; accessed May 31, 2020.
15. Martínez-Martin P, Chaudhuri KR, Rojo-Abuin JM, et al. Assessing the non-motor symptoms of Parkinson's disease: MDS-UPDRS and NMS Scale. *Eur J Neurol*. 2015;22(1):37–43. doi: [10.1111/ene.12165](https://doi.org/10.1111/ene.12165)
16. Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence-based medicine review. *Mov Disord*. 2019;34(2):180–98. doi: [10.1002/mds.27602](https://doi.org/10.1002/mds.27602)
17. Fagerlund K, Anderson LC, Gurvich O. Perioperative medication withholding in patients disease: A retrospective electronic health records review. *Am J Nurs*. 2013;26–35. doi: [10.1097/01.NAJ.0000425744.76107.9f](https://doi.org/10.1097/01.NAJ.0000425744.76107.9f)
18. Rabinak CA, Nirenberg MJ. Dopamine agonist withdrawal syndrome in Parkinson disease. *Arch Neurol*. 2010;67(1):58–63. doi: [10.1001/archneurol.2009.294](https://doi.org/10.1001/archneurol.2009.294)
19. Wijemanne S, Jankovic J. Hand, foot, and spine deformities in parkinsonian disorders. *J Neural Transm*. 2019;126(3):253–64. doi: [10.1007/s00702-019-01986-1](https://doi.org/10.1007/s00702-019-01986-1)
20. Li BY, Lou M. Severe hypothermia in Parkinson's disease. *CNS Neurosci Ther*. 2012;18(10):64–6. doi: [10.1111/j.1755-5949.2012.00375.x](https://doi.org/10.1111/j.1755-5949.2012.00375.x)
21. Renga V, Hickey WF, Bernat JL. Spontaneous periodic hypothermia in Parkinson disease with hypothalamic involvement. *Neurol Clin Pract*. 2017;7(6):538–40. doi: [10.1212/CPJ.0000000000000402](https://doi.org/10.1212/CPJ.0000000000000402)
22. Coon EA, Low PA. Thermoregulation in Parkinson disease. *Handb Clin Neurol*. 2018;157:715–25. doi: [10.1016/B978-0-444-64074-1.00043-4](https://doi.org/10.1016/B978-0-444-64074-1.00043-4)
23. Newman EJ, Grosset DG, Kennedy PGE. The Parkinsonism-hyperpyrexia syndrome. *Neurocrit Care*. 2009;10:136–40. doi: [10.1007/s12028-008-9125-4](https://doi.org/10.1007/s12028-008-9125-4)
24. Hovestadt A, Bogaard JM, Meerwaldt JD, Van der Meche FGA, Stigt J. Pulmonary function in Parkinson's disease. *J Neurol Neurosurg Psychiatry*. 1989;52(3):329–33. doi: [10.1136/jnnp.52.3.329](https://doi.org/10.1136/jnnp.52.3.329)
25. Monteiro L, Souza-Machado A, Valderramas S, Melo A. The effect of Levodopa on pulmonary function in Parkinson's disease: A systematic review and meta-analysis. *Clin Ther*. 2012;1049–55. doi: [10.1016/j.clinthera.2012.03.001](https://doi.org/10.1016/j.clinthera.2012.03.001)
26. Sathyaprabha TN, Kapavarapu PK, Pall PK, Thennarasu K, Raju TR. Pulmonary functions in Parkinson's disease. *Indian J Chest Dis Allied Sci*. 2005;47(4):251–7.
27. Pepper PV, Goldstein MK. Postoperative complications in Parkinson's disease. *J Am Geriatr Soc*. 1999;47(8):967–72. doi: [10.1111/j.1532-5415.1999.tb01292.x](https://doi.org/10.1111/j.1532-5415.1999.tb01292.x)
28. Ebihara S, Saito H, Kanda A, et al. Impaired efficacy of cough in patients with Parkinson disease. *Chest*. 2003;124(3):1009–15. doi: [10.1378/chest.124.3.1009](https://doi.org/10.1378/chest.124.3.1009)
29. Fontana GA, Pantaleo T, Lavorini F, Benvenuti F, Gangemi S. Defective motor control of coughing in Parkinson's disease. *Am J Respir Crit Care Med*. 1998;158(2):458–64. doi: [10.1164/ajrccm.158.2.9705094](https://doi.org/10.1164/ajrccm.158.2.9705094)
30. Potulska A, Friedman A, Królicki L, Sychala A. Swallowing disorders in Parkinson's disease. *Park Relat Disord*. 2003;9(6):349–53. doi: [10.1016/S1353-8020\(03\)00045-2](https://doi.org/10.1016/S1353-8020(03)00045-2)
31. Wang M, Saasouh W, Botsford T, et al. Postoperative stridor and acute respiratory failure after Parkinson disease deep brain stimulator placement: Case report and review of literature. *World Neurosurg*. 2018;111:22–5. doi: [10.1016/j.wneu.2017.11.176](https://doi.org/10.1016/j.wneu.2017.11.176)
32. von Eckardstein KL, Sixel-Döring F, Kazmaier S, Trenkwalder C, Hoover JM, Rohde V. Asphyxia due to laryngeal spasm as a severe complication of awake deep brain stimulation for

- Parkinson's disease: A case report. *BMC Neurol.* 2016;16(1):1–4. doi: [10.1186/s12883-016-0736-7](https://doi.org/10.1186/s12883-016-0736-7)
33. Stirt JA, Frantz RA, Gunz EF, Conolly ME. Anesthesia, catecholamines, and hemodynamics in autonomic dysfunction. *Anesth Analg.* 1982;61(8):701–4. doi: [10.1213/0000539-198208000-00016](https://doi.org/10.1213/0000539-198208000-00016)
 34. Mustafa HI, Fessel JP, Barwise J, et al. Dysautonomia: Perioperative implications. *Anesthesiology.* 2012;205–15. doi: [10.1097/ALN.0b013e31823db712](https://doi.org/10.1097/ALN.0b013e31823db712)
 35. McGrane S, Atria NP, Barwise JA. Perioperative implications of the patient with autonomic dysfunction. *Curr Opin Anaesthesiol.* 2014;365–70. doi: [10.1097/ACO.0000000000000072](https://doi.org/10.1097/ACO.0000000000000072)
 36. Krauss JK, Akeyson EW, Giam P, Jankovic J. Propofol-induced dyskinesias in Parkinson's disease. *Anesth Analg.* 1996;83(2):420–2. doi: [10.1097/0000539-199608000-00037](https://doi.org/10.1097/0000539-199608000-00037)
 37. Dingwall AE. Oculogyric crisis after day case anaesthesia. *Anaesthesia.* 1987;565. doi: [10.1111/j.1365-2044.1987.tb04081.x](https://doi.org/10.1111/j.1365-2044.1987.tb04081.x)
 38. Zabani I, Vaghadia H. Refractory dystonia during propofol anaesthesia in a patient with torticollis-dystonia disorder. *Can J Anaesth.* 1996;43(10):1062–64. doi: [10.1007/BF03011910](https://doi.org/10.1007/BF03011910)
 39. Kalenka A, Schwarz A. Anaesthesia and Parkinson's disease: How to manage with new therapies? *Curr Opin Anaesthesiol.* 2009;419–24. doi: [10.1097/ACO.0b013e32832a4b31](https://doi.org/10.1097/ACO.0b013e32832a4b31)
 40. Deogaonkar A, Deogaonkar M, Lee JYK, Ebrahim Z, Schubert A. Propofol-induced dyskinesias controlled with dexmedetomidine during deep brain stimulation surgery. *Anesthesiology.* 2006;104(6):1337–9. doi: [10.1097/0000542-200606000-00029](https://doi.org/10.1097/0000542-200606000-00029)
 41. Shaikh SI, Verma H. Parkinson's disease and anaesthesia – A review article. *Internet J Anesthesiol.* 2010;55(3):228–34.
 42. Votaw J, Byas-Smith M, Hua J, et al. Interaction of isoflurane with the dopamine transporter. *Anesthesiology.* 2003;98(2):404–11. doi: [10.1097/0000542-200302000-00021](https://doi.org/10.1097/0000542-200302000-00021)
 43. Nicholson G, Pereira AC, Hall GM. Parkinson's disease and anaesthesia. *Br J Anaesth.* 2002;89(6):904–16. doi: [10.1093/bja/aef268](https://doi.org/10.1093/bja/aef268)
 44. Mets B. Acute dystonia after alfentanil in untreated Parkinson's disease. *Anesth Analg.* 1991;72(4):557–8. doi: [10.1213/0000539-199104000-00025](https://doi.org/10.1213/0000539-199104000-00025)
 45. Bailey PL, Wilbrink J, Zwanikken P, Pace NL, Stanley TH. Anesthetic induction with fentanyl. *Anesth Analg.* 1985;64(1):48–53. doi: [10.1213/0000539-198501000-00010](https://doi.org/10.1213/0000539-198501000-00010)
 46. Buxton JA, Gauthier T, Woo Kinshell ML, Godwin J. A 52-year-old man with fentanyl-induced muscle rigidity. *CMAJ.* 2018;190(17):E539–41. doi: [10.1503/cmaj.171468](https://doi.org/10.1503/cmaj.171468)
 47. Ahmad M, Raza T. "jaws of Steel" after very low dose of fentanyl during prebronchoscopy sedation. *J Bronchol Interv Pulmonol.* 2017;24(1):e9–110. doi: [10.1097/LBR.0000000000000329](https://doi.org/10.1097/LBR.0000000000000329)
 48. Zornberg GL, Bodkin JA, Cohen BM. Severe adverse interaction between pethidine and selegiline. *Lancet.* 1991;337(8735):246. doi: [10.1016/0140-6736\(91\)92219-R](https://doi.org/10.1016/0140-6736(91)92219-R)
 49. Gravlee GP. Succinylcholine-induced hyperkalemia in a patient with Parkinson's disease. *Anesth Analg.* 1980;59(6):444–6. doi: [10.1213/0000539-198006000-00012](https://doi.org/10.1213/0000539-198006000-00012)
 50. Roark C, Whicher S, Abosch A. Reversible neurological symptoms caused by diathermy in a patient with deep brain stimulators: Case report. *Neurosurgery.* 2008;62(1):e-256. doi: [10.1227/01.NEU.0000311085.73519.B4](https://doi.org/10.1227/01.NEU.0000311085.73519.B4)
 51. Nutt JG, Anderson VC, Peacock JH, Hammerstad JP, Burchiel KJ. DBS and diathermy interaction induces severe CNS damage. *Neurology.* 2001;56(10):1384–6. doi: [10.1212/WNL.56.10.1384](https://doi.org/10.1212/WNL.56.10.1384)
 52. Weaver J, Kim SJ, Torres A. Cutaneous electrosurgery in a patient with a deep brain stimulator. *Dermatologic Surg.* 1999;25(5):415–7. doi: [10.1046/j.1524-4725.1999.08167.x](https://doi.org/10.1046/j.1524-4725.1999.08167.x)
 53. Epstein MR, Mayer JE, Duncan BW. Use of an ultrasonic scalpel as an alternative to electrocautery in patients with pacemakers. *Ann Thorac Surg.* 1998;65:1802–4. doi: [10.1016/S0003-4975\(98\)00105-2](https://doi.org/10.1016/S0003-4975(98)00105-2)
 54. Kaya E, Totzeck M, Rassaf T. Pulsed electron avalanche knife (PEAK) PlasmaBlade™ in pacemaker and defibrillator procedures. *Eur J Med Res.* 2017;22:49. doi: [10.1186/s40001-017-0292-7](https://doi.org/10.1186/s40001-017-0292-7)
 55. Yeoh TY, Manninen P, Kalia SK, Venkatraghavan L. Anesthesia considerations for patients with an implanted deep brain stimulator undergoing surgery: A review and update. *Can J Anesth.* 2017;64(3):308–19. doi: [10.1007/s12630-016-0794-8](https://doi.org/10.1007/s12630-016-0794-8)
 56. Mars H. Levodopa, carbidopa, and pyridoxine in Parkinson disease: Metabolic interactions. *Arch Neurol.* 1974;30(6):444–7. doi: [10.1001/archneur.1974.00490360020005](https://doi.org/10.1001/archneur.1974.00490360020005)
 57. Hauser RA, Isaacson S, Clinch T, et al. Randomized, placebo-controlled trial of trimethoprim to control nausea and vomiting during initiation and continued treatment with subcutaneous apomorphine injection. *Park Relat Disord.* 2014;20(11):1171–76. doi: [10.1016/j.parkreldis.2014.08.010](https://doi.org/10.1016/j.parkreldis.2014.08.010)
 58. Kim S, Cheon S-M, Suh HS. Association between drug exposure and occurrence of Parkinsonism in Korea: A population-based case-control study. *Ann Pharmacother.* 2019;53(11):1102–10. doi: [10.1177/1060028019859543](https://doi.org/10.1177/1060028019859543)
 59. Lawson RA, McDonald C, Burn DJ. Defining delirium in idiopathic Parkinson's disease: A systematic review. *Park Relat Disord.* 2019;29–39. doi: [10.1016/j.parkreldis.2018.09.025](https://doi.org/10.1016/j.parkreldis.2018.09.025)
 60. Lawson RA, Richardson SJ, Yarnall AJ, Burn DJ, Allan LM. Identifying delirium in Parkinson disease: A pilot study. *Int J Geriatr Psychiatry.* 2020;35(5):547–52. doi: [10.1002/gps.5270](https://doi.org/10.1002/gps.5270)
 61. Kim KH, Kang SY, Shin DA, et al. Parkinson's disease-related non-motor features as risk factors for post-operative delirium in spinal surgery. *PLoS One.* 2018;13(4):1–12. doi: [10.1371/journal.pone.0195749](https://doi.org/10.1371/journal.pone.0195749)
 62. Ebersbach G, Ip CW, Klebe S, et al. Management of delirium in Parkinson's disease. *J Neural Transm.* 2019;905–912. doi: [10.1007/s00702-019-01980-7](https://doi.org/10.1007/s00702-019-01980-7)
 63. Lenka A, Gomathinayagam V, Bahroo L. Approach to the management of psychosis in Parkinson's disease. *Ann Mov Disord.* 2019;2(3):83–90. doi: [10.4103/aomd.aomd_27_19](https://doi.org/10.4103/aomd.aomd_27_19)
 64. Matsumoto H, Sengoku R, Saito Y, Kakuta Y, Murayama S, Imafuku I. Sudden death in Parkinson's disease: A retrospective autopsy study. *J Neurol Sci.* 2014;343(1–2):149–52. doi: [10.1016/j.jns.2014.05.060](https://doi.org/10.1016/j.jns.2014.05.060)
 65. Pennington S, Snell K, Lee M, Walker R. The cause of death in idiopathic Parkinson's disease. *Park Relat Disord.* 2010;16(7):434–7. doi: [10.1016/j.parkreldis.2010.04.010](https://doi.org/10.1016/j.parkreldis.2010.04.010)
 66. Sakakibara R, Panicker J, Finazzi-Agro E, Iacovelli V, Bruschini H. A guideline for the management of bladder dysfunction in Parkinson's disease and other gait disorders. *Neurourol Urodyn.* 2016;551–563. doi: [10.1002/nau.22764](https://doi.org/10.1002/nau.22764)
 67. Agrawal K, Majhi S, Garg R. Post-operative urinary retention: Review of literature. *World J Anesthesiol.* 2019;8(1):1–12. doi: [10.5313/wja.v8.i1.1](https://doi.org/10.5313/wja.v8.i1.1)
 68. Tambyah PA, Oon J. Catheter-associated urinary tract infection. *Curr Opin Infect Dis.* 2012;365–70. doi: [10.1097/QCO.0b013e32835565cc](https://doi.org/10.1097/QCO.0b013e32835565cc)